SOURCE: SRI International

November 14, 2007 08:30 ET

SRI International Awarded National Institute of Allergy and Infectious Diseases Contract to Develop Drugs and Therapeutics for HIV and AIDS-Associated Infections

MENLO PARK, CA--(Marketwire - November 14, 2007) - SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a $15.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide preclinical services for the development of drugs and therapeutic vaccines for the treatment of HIV and opportunistic infections commonly associated with HIV infection and AIDS.

SRI International will provide a variety of preclinical services in support of development of new therapies including toxicology, pharmacology, pharmacokinetics, toxicogenomics, and other testing requirements to support submission of Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA).

The contract is a continuation of a NIAID contract held by SRI International since 1991. Over the past 16 years, SRI International has provided preclinical services in support of over 200 drugs and therapeutic vaccines at various stages of development.

"We are excited to be able to continue supporting NIAID's Division of AIDS in this important preclinical program," said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI International's Biosciences Division and Principal Investigator for the program. "This major project, coupled with the related programs for analytical chemistry, formulation, and clinical manufacturing that SRI International also holds, allows us to contribute significantly to AIDS therapeutic development."

In addition to this contract for anti-infective therapeutic development, SRI International also holds major NIAID programs for the development of drugs for other infectious diseases. In 2006, SRI International won a $57M contract for development of anti-infectives for many viral and bacterial diseases.

About SRI International's Biosciences Division

SRI International's Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI International Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI International has all of the resources necessary to take R&D programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials -- and specializes in cancer, immunology, infectious disease, and neuroscience research. To date, SRI International has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI International is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI International has been meeting the strategic needs of clients for 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI International licenses its technologies, forms strategic partnerships, and creates spin-off companies.

Contact Information